Dr Reddy’s Laboratories has acquired the India trademarks of two hormone replacement therapy drugs from Mercury Pharma for $32.15 million, strengthening its women’s health portfolio and marking its entry into the growing HRT segment.
Eli Lilly is establishing India as a strategic center point in its global supply chain, with the assistance of the robust contract manufacturing ecosystem
Roche has announced a major breakthrough in primary membranous nephropathy after its Phase III MAJESTY trial showed higher complete remission rates with Gazyva/Gazyvaro compared to tacrolimus, marking a potential shift in rare kidney disease care.
Rx Propellant is scaling up in Genome Valley with a USD 100 million investment in a new life sciences campus. The move strengthens Hyderabad’s global biotech standing and meets rising demand for advanced lab space.
Teva and Sanofi reveal duvakitug’s 44-week success, showing lasting remission in ulcerative colitis and Crohn’s patients, reinforcing TL1A as a promising treatment target.
Aster Volunteers launches two new Mobile Medical Units in Tirupati and Anekal, expanding healthcare access in underserved communities across India.
Eli Lilly’s Retevmo delivers significant gains in event-free survival for early-stage RET fusion-positive NSCLC, marking a breakthrough in targeted lung cancer therapy.
Lupin partners with Spektus Pharma to launch DeslaFlex in Canada, enhancing its CNS portfolio and offering patients a novel treatment option for Major Depressive Disorder.
Courage met opportunity in Haridwar as Akums hosted a three-day skill camp for acid attack and burn survivors, helping them step into corporate life with confidence and purpose.
The USFDA has completed its inspection of Enzene’s manufacturing unit in Chakan, Pune, issuing six procedural observations with no data integrity issues. The outcome strengthens the company’s compliance standing in regulated markets.